touchRESPIRATORY caught up with Dr. Vijay Balasubramanian (UCSF Fresno, Fresno, CA, USA) to learn more around the challenges associated with treprostinil therapy in pulmonary arterial hypertension (PAH) and the impact treprostinil has had on the treatment paradigm since its approval.
The abstract ‘Rapid Titration of Parenteral Treprostinil to EXPEDITE Dosing of Oral Treprostinil‘ (Abstract number: P203) was presented at ATS 2022, 13-18 May 2022.
Questions
- What are the challenges of treprostinil therapy in patients with pulmonary arterial hypertension (PAH)? (0:40)
- Since its approval, what has been the impact of treprostinil on the treatment paradigm for PAH? (2:53)
Disclosures: Vijay Balasubramanian discloses receiving grant/ research support from United Therapeutics and has participated in speaker’s bureaus for Bayer, Janssen, and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
